Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Inclusion Criteria: * Had received two-dose priming vaccination in previous phase I trial * Be able to show legal identity card for the sake of recruitment * Be able to understand and sign the informed consent. Exclusion Criteria: * Woman： Who breast-feeding or planning to become pregnant during the study * Any history of allergic reactions to vaccines or eggs * Autoimmune disease or immunodeficiency * Diabetes mellitus (type I or II), with the exception of gestational diabetes * Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years * Hypertension that was not well controlled by medication or is more than 145/95 mmHg at enrollment * Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study * Guillain-Barre Syndrome * Women subjects with positive urinary pregnancy test * Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months * History of any blood products administration within 3 months before the dosing * Administration of any other investigational research agents within 30 days before the dosing * Administration of any live attenuated vaccine within 30 days before the dosing * Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing * Be receiving …